The Filing Desk

Cytek Biosciences vs Ginkgo Bioworks

Cytek Biosciences CTKB · Ginkgo Bioworks DNA · Life Sciences Tools & Services

Cytek Biosciences reported revenue of $202 million in fiscal 2025, 1.2 times Ginkgo Bioworks' $170 million in fiscal 2025. Cytek Biosciences' revenue grew 0.5% in its latest year, and Ginkgo Bioworks' fell 25.1%. Cytek Biosciences had an operating margin of -20.0%, against -185.3% at Ginkgo Bioworks. Free cash flow was −$9 million at Cytek Biosciences and −$179 million at Ginkgo Bioworks.

Side by side

Cytek BiosciencesGinkgo Bioworks
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$202M$170M
Revenue growth0.5%−25.1%
Revenue growth a year, last 5 years210.3%17.3%
Gross margin51.8%—
Operating margin−20.0%−185.3%
Net margin−33.0%−183.8%
Free cash flow−$9M−$179M
Free cash flow margin−4.3%−105.0%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$15M$0M
Change in diluted share count−2.2%6.9%
Last close$5.84$9.61
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cytek BiosciencesGinkgo Bioworks
Operating margin
Percent of revenue
Cytek BiosciencesGinkgo Bioworks
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cytek BiosciencesGinkgo Bioworks

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cytek Biosciences and Ginkgo Bioworks pages.